Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
BB-1701 + sintilimab
- Development stage
- Unknown
- Lead developer
- 百力司康
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
BB-1701 + sintilimab is an investigational combination regimen consisting of BB-1701, a HER2-targeting antibody-drug conjugate (ADC), and sintilimab, a programmed cell death protein 1 (PD-1) blocking monoclonal antibody. BB-1701 is composed of a humanized anti-HER2 IgG1 monoclonal antibody conjugated to the microtubule inhibitor eribulin via a cleavable Mc-PEG2-Val-Cit-PABC linker. Sintilimab is a fully human IgG4 monoclonal antibody that blocks the interaction between PD-1 and its ligands (PD-L1 and PD-L2), thereby restoring T-cell mediated antitumor immune responses. The combination is being evaluated in Phase II clinical trials for the treatment of HER2-expressing or HER2-mutated advanced or metastatic solid tumors, including HER2-low breast cancer and HER2-mutant non-small cell lung cancer (NSCLC).
- Other names
- BB 1701 + sintilimabBB-1701 plus sintilimabBB1701 plus sintilimabBB 1701 plus sintilimabBB1701 + sintilimabsintilimab + BB 1701sintilimab + BB-1701sintilimab + BB1701
02
Targets
PDCD1 (Programmed cell death protein 1 receptor)ERBB2 (Erb-b2 receptor tyrosine kinase 2)
Beyond the preview
Go deeper on BB-1701 + sintilimab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on BB-1701 + sintilimab.